因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

未开盘 01-08 16:00:00 EST

105.92

-4.65

-4.21%

盘后106.41

+0.49+0.46%

19:50 EST

最高110.09	最低104.69	成交量257.84万
今开109.74	昨收110.57	日振幅4.88%
总市值207.95亿	流通市值172.69亿	总股本1.96亿
成交额2.75亿	换手率1.58%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":105.92,"timestamp":1767906000000,"preClose":110.57,"halted":0,"volume":2578423,"hourTrading":{"tag":"盘后","latestPrice":106.4065,"preClose":105.92,"latestTime":"19:50 EST","volume":75055,"amount":7950307.4776,"timestamp":1767919828261},"delay":0,"floatShares":163042517,"shares":196322703,"eps":5.90299,"marketStatus":"未开盘","change":-4.65,"latestTime":"01-08 16:00:00 EST","open":109.74,"high":110.09,"low":104.69,"amount":274548660.673362,"amplitude":0.048838,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.90299,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767949200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":110.57,"preHourTrading":{"tag":"盘前","latestPrice":109.66,"preClose":110.57,"latestTime":"09:28 EST","volume":22038,"amount":2465986.96752,"timestamp":1767882529716},"postHourTrading":{"tag":"盘后","latestPrice":106.4065,"preClose":105.92,"latestTime":"19:50 EST","volume":75055,"amount":7950307.4776,"timestamp":1767919828261},"volumeRatio":0.933141,"impliedVol":0.4232,"impliedVolPercentile":0.564},"requestUrl":"/m/hq/s/INCY","defaultTab":"news","newsList":[{"id":"1110439004","title":"因塞特医疗股价盘前涨2.8%，血癌疗法达晚期试验主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1110439004","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110439004?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:53","pubTimestamp":1767617594,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）股价在盘前交易中上涨2.8%，此前该公司宣布其血癌疗法在晚期临床试验中达到了主要研究目标。这一积极进展提振了投资者信心，推动股价走高。\n该疗法在关键试验阶段的表现超出预期，为后续监管申请奠定了坚实基础。市场密切关注该疗法能否最终获批上市，从而为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4532","INCY","BK4588","BK4139","BK4550"],"gpt_icon":0},{"id":"1146871643","title":"因塞特医疗计划于2026年上半年提交Tafasitamab一线治疗新诊断DLBCL成人患者的补充生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1146871643","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146871643?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:32","pubTimestamp":1767616336,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，公司预计将在2026年上半年为Tafasitamab提交一份补充生物制剂许可申请，旨在将其用于一线治疗新诊断的弥漫性大B细胞淋巴瘤成人患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4532","BK4139","INCY","BK4588","BK4585"],"gpt_icon":0},{"id":"1112426504","title":"因塞特医疗公布Tafasitamab（Monjuvi®/Minjuvi®）作为弥漫性大B细胞淋巴瘤一线治疗关键研究的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112426504","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112426504?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:30","pubTimestamp":1767616259,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其关键临床研究取得积极顶线数据，评估Tafasitamab（商品名Monjuvi®/Minjuvi®）作为弥漫性大B细胞淋巴瘤（DLBCL）一线治疗方案的效果。该结果标志着该药物在早期治疗应用中的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4532","BK4550","BK4139","BK4588","INCY"],"gpt_icon":0},{"id":"1178257358","title":"因塞特医疗在日本获批Zynyz®（Retifanlimab）用于晚期肛门癌的一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1178257358","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178257358?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:46","pubTimestamp":1766389562,"startTime":"0","endTime":"0","summary":"因塞特医疗在日本获批Zynyz®（Retifanlimab）用于晚期肛门癌的一线治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4532","BK4550","BK4585","INCY"],"gpt_icon":0},{"id":"1119754749","title":"因塞特医疗宣布Minjuvi®（Tafasitamab）与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1119754749","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119754749?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:44","pubTimestamp":1766389475,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，Minjuvi®（Tafasitamab）与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","BK4585","BK4550","BK4588","INCY"],"gpt_icon":0},{"id":"2592155281","title":"AI狂欢过后如何备战2026？这四只“攻守兼备”的防御性股票值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2592155281","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592155281?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:05","pubTimestamp":1766127943,"startTime":"0","endTime":"0","summary":"如果2026年科技板块降温且经济增长保持温和而非强劲，这些公司可能成为当前值得买入的最佳防御性股票。收益率、通胀保护和盈利增长的结合，使该公司成为2026年防御性配置的基础性持仓。Iberdrola的基本面优势已转化为其在2025年表现动量方面的板块领先地位，这一势头在2026年有望延续。这些股票共同表明，防御性投资不一定枯燥或停滞不前，2026年最佳的防御性股票可能是那些既能保护资本，又能选择性实现资本增长的标的。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85e8aafb51ba0ad706197d405ff70b96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383591.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AI狂欢过后如何备战2026？这四只“攻守兼备”的防御性股票值得关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBDRY","VRTX","INCY","BRKR"],"gpt_icon":1},{"id":"1177744150","title":"因塞特医疗宣布Minjuvi®（Tafasitamab）获欧洲委员会批准用于治疗复发性或难治性滤泡性淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1177744150","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177744150?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:21","pubTimestamp":1765988505,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布Minjuvi®（Tafasitamab）获欧洲委员会批准用于治疗复发性或难治性滤泡性淋巴瘤","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","INCY","BK4550","BK4532"],"gpt_icon":0},{"id":"1156411721","title":"因塞特医疗：HervÉ Hoppenot于12月10日通知即刻退休，辞去公司董事会职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1156411721","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156411721?lang=zh_cn&edition=full","pubTime":"2025-12-13 00:37","pubTimestamp":1765557437,"startTime":"0","endTime":"0","summary":"因塞特医疗：HervÉ Hoppenot于12月10日通知即刻退休，辞去公司董事会职务","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4585","INCY","BK4550","BK4139"],"gpt_icon":0},{"id":"1107497688","title":"因塞特医疗在2025年ASH大会上发布更新的积极数据，巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1107497688","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107497688?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:39","pubTimestamp":1765229946,"startTime":"0","endTime":"0","summary":"因塞特医疗在2025年ASH大会上发布更新的积极数据，巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4550","BK4532","BK4139","BK4585","INCY"],"gpt_icon":0},{"id":"1127664241","title":"因塞特医疗公布首款Mutcalr靶向单克隆抗体Inca033989在骨髓纤维化患者中的积极新数据，发布于2025年ASH会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1127664241","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127664241?lang=zh_cn&edition=full","pubTime":"2025-12-07 22:31","pubTimestamp":1765117873,"startTime":"0","endTime":"0","summary":"因塞特医疗公布首款Mutcalr靶向单克隆抗体Inca033989在骨髓纤维化患者中的积极新数据，发布于2025年ASH会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INCY","BK4588","BK4585","BK4532","BK4550"],"gpt_icon":0},{"id":"1175139923","title":"因塞特医疗公布Minjuvi®（Tafasitamab）治疗复发性或难治性滤泡淋巴瘤的积极CHMP意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1175139923","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175139923?lang=zh_cn&edition=full","pubTime":"2025-11-17 14:01","pubTimestamp":1763359281,"startTime":"0","endTime":"0","summary":"因塞特医疗公布Minjuvi®（Tafasitamab）治疗复发性或难治性滤泡淋巴瘤的积极CHMP意见","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4585","BK4532","INCY","BK4139","BK4588"],"gpt_icon":0},{"id":"1168884106","title":"摩根士丹利：这些“潜在分红股”若启动派息，或将带来可观回报","url":"https://stock-news.laohu8.com/highlight/detail?id=1168884106","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168884106?lang=zh_cn&edition=full","pubTime":"2025-11-11 11:20","pubTimestamp":1762831244,"startTime":"0","endTime":"0","summary":"根据摩根士丹利的分析，一些美股公司具备财务实力，有能力开始向股东支付股息。为了寻找这些“潜在分红股”，卡斯塔尼奥筛选出了那些目前尚未支付季度股息、净现金占市值比例超过5%、自由现金流收益率高于3%的公司。摩根士丹利指出，Schwab的净现金占市值比例为12.3%，自由现金流收益率为8.7%。其股价年初至今上涨约29%。Twilio预计2025年的自由现金流将在9.2亿至9.3亿美元之间。其股价今年迄今上涨近21%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a9184b88c2cdb4d7f1e15ff04a6a973","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BMRN","NYT","DDS","SCHW","CART","SAM","TWLO","ABNB","LYFT"],"gpt_icon":1},{"id":"1198838550","title":"Prelude Therapeutics与因塞特医疗签署独家选择权协议以推进选择性Jak2v617f Jh2抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1198838550","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198838550?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:03","pubTimestamp":1762257795,"startTime":"0","endTime":"0","summary":"Prelude Therapeutics与因塞特医疗签署独家选择权协议，以推动选择性Mutant Selective Jak2v617f Jh2抑制剂的研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRLD","BK4588","BK4505","BK4532","BK4139","INCY","BK4585","BK4550"],"gpt_icon":0},{"id":"1115847975","title":"因塞特医疗公布Opzelura®（Ruxolitinib Cream）在中度特应性皮炎成人患者中进行的3B期True-AD4试验新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847975","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115847975?lang=zh_cn&edition=full","pubTime":"2025-10-26 07:56","pubTimestamp":1761436571,"startTime":"0","endTime":"0","summary":"因塞特医疗公布Opzelura®（Ruxolitinib Cream）在中度特应性皮炎成人患者中进行的3B期True-AD4试验新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4585","INCY","BK4550","BK4139"],"gpt_icon":0},{"id":"1175003126","title":"因塞特医疗：加拿大卫生部批准Opzelura（鲁索替尼）乳膏用于2-11岁儿童特应性皮炎治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1175003126","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175003126?lang=zh_cn&edition=full","pubTime":"2025-10-15 19:04","pubTimestamp":1760526257,"startTime":"0","endTime":"0","summary":"因塞特医疗：加拿大卫生部批准Opzelura（鲁索替尼）乳膏用于2-11岁儿童特应性皮炎治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4532","BK4139","INCY","BK4550"],"gpt_icon":0},{"id":"1118262917","title":"因塞特医疗宣布任命Dave Gardner为执行副总裁兼首席战略官","url":"https://stock-news.laohu8.com/highlight/detail?id=1118262917","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118262917?lang=zh_cn&edition=full","pubTime":"2025-09-22 19:31","pubTimestamp":1758540679,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布任命Dave Gardner担任公司执行副总裁兼首席战略官职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4532","BK4550","BK4585","INCY"],"gpt_icon":0},{"id":"1154956006","title":"因塞特医疗宣布Opzelura®（鲁索替尼）乳膏获FDA批准用于治疗2-11岁儿童特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1154956006","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154956006?lang=zh_cn&edition=full","pubTime":"2025-09-19 04:22","pubTimestamp":1758226938,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布Opzelura®（鲁索替尼）乳膏获FDA批准用于治疗2-11岁儿童特应性皮炎","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4532","BK4585","BK4550","BK4588","INCY"],"gpt_icon":0},{"id":"1125458054","title":"因塞特医疗在EADV 2025大会上公布Povorcitinib治疗化脓性汗腺炎Stop-Hs临床试验项目新的24周3期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125458054","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125458054?lang=zh_cn&edition=full","pubTime":"2025-09-17 13:01","pubTimestamp":1758085290,"startTime":"0","endTime":"0","summary":"因塞特医疗在EADV 2025大会上公布Povorcitinib治疗化脓性汗腺炎Stop-Hs临床试验项目新的24周3期数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","BK4139","BK4550","BK4532","BK4585"],"gpt_icon":0},{"id":"1197726548","title":"因塞特医疗任命Soni Basi为执行副总裁兼首席人力资源官","url":"https://stock-news.laohu8.com/highlight/detail?id=1197726548","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197726548?lang=zh_cn&edition=full","pubTime":"2025-08-25 20:04","pubTimestamp":1756123440,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，任命Soni Basi为公司执行副总裁兼首席人力资源官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4550","BK4532","BK4585","BK4588","INCY"],"gpt_icon":0},{"id":"2558690963","title":"因塞特8月11日成交额为1.59亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558690963","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558690963?lang=zh_cn&edition=full","pubTime":"2025-08-12 11:11","pubTimestamp":1754968314,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，因塞特成交额为1.59亿美元，成交额较昨日增加69.48%，当日成交量为201.58万股。因塞特于2025年8月11日涨1.02%，报79.19美元，该股过去5个交易日涨1.47%，年初至今涨14.65%，过去60日涨29.48%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-11|1.59亿|69.48%|201.58万|#|2025-08-08|9409.23万|-14.67%|120.03万|#|2025-08-07|1.10亿|-28.31%|141.69万|#|2025-08-06|1.54亿|14.14%|198.79万|#|2025-08-05|1.35亿|7.26%|173.36万|Incyte专注于小分子药物的发现与研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812111159a6e0b994&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812111159a6e0b994&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4550","INCY","BK4532","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":0.0724},{"period":"1month","weight":0.1131},{"period":"3month","weight":0.264},{"period":"6month","weight":0.5442},{"period":"1year","weight":0.4484},{"period":"ytd","weight":0.0724}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司，致力于专有疗法的发现、开发和商业化。该公司专注于两个治疗领域，这两个领域由其获批药物的适应症和其临床候选药物正在开发的疾病定义。一个治疗领域是血液学/肿瘤学，包括骨髓增生性肿瘤(MPN)、移植物抗宿主病(GVHD)、实体瘤和血液系统恶性肿瘤。另一个治疗领域是炎症和自身免疫(IAI)，包括其皮肤病学商业特许经营权。该公司还有权获得其发现并授权给第三方的分子的里程碑和特许权使用费。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.085981},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.001863},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.038633},{"month":4,"riseRate":0.46875,"avgChangeRate":-0.011198},{"month":5,"riseRate":0.625,"avgChangeRate":0.061854},{"month":6,"riseRate":0.59375,"avgChangeRate":0.024163},{"month":7,"riseRate":0.53125,"avgChangeRate":0.01586},{"month":8,"riseRate":0.53125,"avgChangeRate":0.019237},{"month":9,"riseRate":0.40625,"avgChangeRate":-0.019519},{"month":10,"riseRate":0.53125,"avgChangeRate":0.026823},{"month":11,"riseRate":0.59375,"avgChangeRate":0.061387},{"month":12,"riseRate":0.59375,"avgChangeRate":0.093713}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}